#1 Clinical Trials Search in Europe

Clofarabine

Clofarabine is an innovative chemotherapy drug being studied in clinical trials for various blood cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). This article summarizes key findings from recent clinical trials exploring clofarabine’s efficacy, safety, and potential as a treatment option for patients with limited alternatives.

Table of Contents

What is Clofarabine?

Clofarabine is a chemotherapy drug designed to interfere with the growth and development of cancer cells[8]. It belongs to a class of medications called purine nucleoside analogs[2]. Clofarabine is known by several names, including:

  • Clolar® (U.S. trade name)
  • Evoltra® (European trade name)
  • Clofarex

The U.S. Food and Drug Administration (FDA) has approved clofarabine for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL)[8]. However, its use in other conditions and age groups is still being investigated in clinical trials.

What Conditions Does Clofarabine Treat?

Clofarabine is used to treat various blood cancers and related disorders, including:

  • Acute Lymphoblastic Leukemia (ALL): A type of blood cancer that affects white blood cells called lymphocytes[3].
  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow that affects myeloid cells[4].
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[5].
  • Non-Hodgkin Lymphoma (NHL): A type of cancer that starts in white blood cells called lymphocytes[1].
  • Chronic Lymphocytic Leukemia (CLL): A slow-growing cancer of the blood and bone marrow[7].

How Does Clofarabine Work?

Clofarabine works by interfering with the DNA synthesis and repair processes in cancer cells[1]. It does this in several ways:

  1. It inhibits an enzyme called DNA polymerase, which is necessary for DNA replication.
  2. It causes damage to the DNA structure.
  3. It induces apoptosis, which is a process of programmed cell death.

By disrupting these cellular processes, clofarabine can slow down or stop the growth of cancer cells, potentially leading to their destruction.

How is Clofarabine Administered?

Clofarabine can be administered in two main ways:

  1. Intravenous (IV) infusion: This is the most common method. Clofarabine is given through a vein over a period of 1-2 hours[6].
  2. Oral tablets: Some clinical trials are investigating the use of clofarabine in tablet form[8].

The dosage and schedule can vary depending on the specific condition being treated, the patient’s age, and other factors. Typically, clofarabine is given in cycles, with treatment days followed by rest periods to allow the body to recover[1].

Effectiveness of Clofarabine

Clinical trials have shown promising results for clofarabine in various blood cancers:

  • In pediatric patients with relapsed or refractory ALL, clofarabine has shown an overall remission rate of about 20%[3].
  • For AML patients, studies have reported response rates ranging from 3% to 23%[6].
  • In MDS patients who have failed previous treatments, clofarabine has shown some effectiveness in improving blood cell counts and reducing the need for transfusions[5].

It’s important to note that the effectiveness can vary greatly depending on the individual patient, the specific type and stage of cancer, and previous treatments received.

Potential Side Effects

Like all chemotherapy drugs, clofarabine can cause side effects. Some of the most common include:

  • Nausea and vomiting
  • Fatigue
  • Fever
  • Decreased blood cell counts (which can lead to increased risk of infection, anemia, and bleeding)
  • Skin rash
  • Diarrhea

More serious side effects can occur, including liver problems and a condition called tumor lysis syndrome, where the rapid breakdown of cancer cells can cause metabolic disturbances[6]. Your healthcare team will monitor you closely for these and other potential side effects.

Ongoing Research and Future Directions

Researchers continue to study clofarabine to understand its full potential in treating blood cancers. Some areas of ongoing research include:

  • Using clofarabine in combination with other chemotherapy drugs to improve effectiveness[6].
  • Investigating oral formulations of clofarabine for easier administration[4].
  • Studying clofarabine as part of conditioning regimens before stem cell transplants[6].
  • Exploring its use in older patients with AML who may not be able to tolerate more intensive chemotherapy regimens[2].

These ongoing studies aim to optimize the use of clofarabine and potentially expand its applications in cancer treatment.

Aspect Details
Cancer Types Studied Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Lymphocytic Leukemia (CLL)
Administration Methods Intravenous infusion, Oral tablets
Dosing Schedules Varies by trial: daily for 5 days, weekly, or other regimens
Key Outcomes Measured Overall response rate, Complete remission, Partial remission, Duration of response, Overall survival
Patient Populations Pediatric and adult patients, Relapsed/refractory disease, Newly diagnosed patients unfit for intensive chemotherapy
Combination Therapies Used alone or in combination with other drugs (e.g., cytarabine) or before stem cell transplantation
Safety Considerations Monitoring for side effects, Dose adjustments based on tolerability, Investigation of drug interactions

FAQ

  • What is clofarabine? Clofarabine is a chemotherapy drug designed to interfere with the growth and development of cancer cells. It is a second-generation purine nucleoside analog that has shown promise in treating various blood cancers.
  • What types of cancer is clofarabine being studied for? Clinical trials are investigating clofarabine for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic lymphocytic leukemia (CLL).
  • How is clofarabine administered? Clofarabine can be given intravenously (through a vein) or orally (by mouth) as tablets. The dosing schedule varies depending on the specific trial and condition being treated.
  • What are some potential side effects of clofarabine? Common side effects may include low blood counts, nausea, vomiting, and fatigue. More serious side effects can occur, which is why patients are closely monitored during clinical trials.
  • Is clofarabine approved for use outside of clinical trials? Clofarabine is FDA-approved for treating pediatric patients with relapsed or refractory acute lymphoblastic leukemia. Its use in other conditions and age groups is still considered experimental and being studied in clinical trials.

Ongoing Clinical Trials on Clofarabine

  • Study of Cytarabine, Daunorubicin, and Clofarabine for Children with Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Denmark Germany Italy The Netherlands Spain

  • Study on Graft-Versus-Host Disease Prevention Using Cyclophosphamide and Methotrexate in Adults with Blood Cancer Undergoing Matched-Donor Transplant

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Conditioning Treatments with Busulfan, Clofarabine, and Fludarabine for Children with Acute Myeloid Leukemia Undergoing Stem Cell Transplantation

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark Finland The Netherlands Norway Sweden

  • Study Comparing Clofarabine/Busulfan and Fludarabine/Busulfan for Adults with Acute Myeloid Leukemia Eligible for Stem Cell Transplantation

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study of Clofarabine for Patients with Advanced or Metastatic Bladder Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Austria

Glossary

  • Acute Lymphoblastic Leukemia (ALL): A type of blood cancer that affects the white blood cells called lymphocytes. It progresses rapidly and requires immediate treatment.
  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the myeloid line of blood cells, including red blood cells, platelets, and certain white blood cells. It progresses quickly and requires prompt treatment.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow does not produce enough healthy blood cells. It can sometimes progress to acute myeloid leukemia.
  • Chronic Lymphocytic Leukemia (CLL): A slow-growing cancer of the blood and bone marrow that affects lymphocytes, a type of white blood cell.
  • Allogeneic Stem Cell Transplant: A procedure where a patient receives blood-forming stem cells from a genetically similar, but not identical, donor to replace damaged or diseased bone marrow.
  • Complete Remission (CR): A treatment response where there are no detectable cancer cells in the body and blood counts have returned to normal levels.
  • Partial Remission (PR): A treatment response where there is a significant reduction in cancer cells, but they are still detectable.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.

References

  1. https://clinicaltrials.gov/study/NCT00156013
  2. https://clinicaltrials.gov/study/NCT00924443
  3. https://clinicaltrials.gov/study/NCT00930098
  4. https://clinicaltrials.gov/study/NCT01169012
  5. https://clinicaltrials.gov/study/NCT00700011
  6. https://clinicaltrials.gov/study/NCT00529360
  7. https://clinicaltrials.gov/study/NCT00081887
  8. https://clinicaltrials.gov/study/NCT00299156